Effects of Radioactive Iodine on the Immune System in Thyroid Cancer
Launched by RADBOUD UNIVERSITY MEDICAL CENTER · Aug 4, 2023
Trial Information
Current as of September 10, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at how radioactive iodine treatment affects the immune system in patients with a specific type of thyroid cancer called non-medullary thyroid carcinoma. Researchers will collect blood samples from patients one month before they receive radioactive iodine treatment and again two months after treatment. They will focus on certain immune cells, called monocytes, to see how their numbers and functions change due to the treatment. The study will compare results from patients who are receiving treatment to prevent cancer from coming back and those who have ongoing cancer.
To join this trial, participants must be at least 18 years old and have a confirmed diagnosis of non-medullary thyroid cancer. They should be planning to receive radioactive iodine treatment, either to help prevent cancer from returning or to treat ongoing disease. However, people with certain conditions—like infections, those taking certain medications that affect the immune system, or women who are pregnant—won't be eligible. Participants can expect to provide blood samples at two different times, and the study aims to better understand how treatment may impact their immune system, which could help improve care for future patients.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Pathologically confirmed non-medullary thyroid cancer
- • Undergoing radioactive iodine treatment in an adjuvant setting or for persistent structural disease
- • Aged ≥ 18 years
- Exclusion Criteria:
- • Inflammatory or infectious comorbidities
- • Using medication interfering with the immune system
- • Pregnancy
- • A self-reported alcohol consumption of \>21 units per week
- • Other active malignancies, defined as malignancies not in complete remission for \<2 years
- • Previous systemic anti-cancer treatment such as chemotherapy, targeted therapy, radiotherapy or immunotherapy within 3 years before study procedures
About Radboud University Medical Center
Radboud University Medical Center is a leading academic medical institution located in Nijmegen, the Netherlands, dedicated to advancing healthcare through innovative research and education. As a prominent sponsor of clinical trials, Radboud UMC leverages its multidisciplinary expertise to conduct high-quality research that aims to improve patient outcomes and enhance medical knowledge. The center is committed to ethical standards and regulatory compliance, fostering collaboration among researchers, healthcare professionals, and patients to translate scientific discoveries into effective clinical applications. With a focus on personalized medicine and cutting-edge technologies, Radboud University Medical Center plays a pivotal role in shaping the future of healthcare through its rigorous clinical trial initiatives.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Nijmegen, Netherlands
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported